Vitamin B12 Deficiency Symptoms: Testing, Pernicious Anemia, and Treatment

When Numbers Lie: The Testing Problem

Standard serum vitamin B12 testing misses roughly 50% of true functional deficiency cases, according to research published in the Journal of Clinical Pathology. The test measures total cobalamin in serum, but biologically inactive analogues — particularly from certain algae and fermented foods — are measured alongside active cobalamin and can falsely elevate the result. A person with a serum B12 of 300 pg/mL (generally considered normal) may still have severe intracellular deficiency causing progressive neurological damage. The solution has been available since the 1990s: methylmalonic acid (MMA) and homocysteine testing. Both accumulate when B12-dependent enzymatic reactions stall, providing a functional rather than simply a quantitative measure of sufficiency.

Neurological and Hematological Consequences

Vitamin B12 (cobalamin) is required for two enzymatic reactions in humans. Methylcobalamin is the cofactor for methionine synthase, which converts homocysteine to methionine and regenerates the active form of folate. Adenosylcobalamin is the cofactor for methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA — a key step in odd-chain fatty acid and amino acid catabolism. Deficiency disrupts both pathways simultaneously.

• Megaloblastic anemia: Impaired DNA synthesis in rapidly dividing cells causes enlarged, immature red blood cells with reduced oxygen-carrying capacity. Fatigue, pallor, and dyspnea result.
• Subacute combined degeneration of the spinal cord: Demyelination of the posterior and lateral columns causes symmetrical tingling in hands and feet, gait ataxia, and eventually spastic paresis. This is irreversible if untreated for months to years.
• Cognitive impairment: B12 deficiency is associated with elevated homocysteine, a neurotoxin that damages endothelium and accelerates brain atrophy. A 2008 study in Neurology found B12-deficient adults had more rapid brain volume loss over 5 years.
• Glossitis: Smooth, painful, magenta-colored tongue due to atrophy of lingual papillae — a clinical sign easily overlooked.

Pernicious Anemia: Autoimmune B12 Malabsorption

Pernicious anemia (PA) is an autoimmune gastritis in which antibodies attack parietal cells and intrinsic factor (IF). Intrinsic factor, secreted by gastric parietal cells, is essential for ileal absorption of cobalamin. Without IF, only ~1% of dietary B12 is passively absorbed (compared to ~50% via IF-mediated transport). PA accounts for 20–30% of B12 deficiency in adults over 60 in Western countries. Diagnosis rests on detecting anti-intrinsic factor antibodies (specificity ~95%, sensitivity ~50%) or anti-parietal cell antibodies (sensitivity ~85%, specificity ~70%). Atrophic gastritis — the same inflammatory process without detectable antibodies — causes an additional significant proportion of cases. PA carries a roughly 3-fold increased risk of gastric carcinoid tumors and requires lifelong treatment.

High-Risk Groups

Several populations face elevated deficiency risk:

• Vegans and strict vegetarians: B12 occurs naturally only in animal-sourced foods. No plant food provides reliable bioavailable cobalamin (seaweed analogues are inactive). Deficiency develops in 50–80% of unsupplemented vegans within years.
• Metformin users: Metformin reduces ileal calcium-dependent B12 absorption; after 4 years of use, 30% of patients show biochemical B12 deficiency (DPP Outcomes Study data).
• Adults over 60: Atrophic gastritis affects up to 30% of adults over 60, impairing protein-bound B12 release from food (though free crystalline B12 in supplements absorbs normally).
• Post-gastric bypass patients: Reduced parietal cell mass and rapid gastric emptying impair both IF production and acid-mediated food-B12 release.

Sublingual vs. Injection: What the Evidence Shows

Intramuscular (IM) hydroxocobalamin injection bypasses all gastrointestinal absorption steps and was historically considered the gold standard for pernicious anemia. A systematic review in the Cochrane Database (updated 2018) found that high-dose oral cyanocobalamin (1,000–2,000 µg/day) was as effective as IM injection at normalizing serum B12 and MMA in most patients — including those with pernicious anemia — because approximately 1% of any dose absorbs passively across intestinal mucosa without intrinsic factor.

Sublingual formulations (dissolved under the tongue for buccal absorption) are marketed as superior to oral tablets, but clinical trial evidence does not consistently support an advantage over standard oral high-dose supplementation. The choice between injection and high-dose oral/sublingual supplementation is clinically equivalent for most patients; injection remains preferred where adherence to daily oral dosing is uncertain.

This article is for informational purposes only. Consult a qualified healthcare professional.